A stimulating advance in erythropoiesis for patients with myelodysplastic syndromes |
Jul 2024 |
Lancet Haematology |
Myelodysplastic Syndromes (MDS) |
Low dose lenalidomide versus placebo in non-transfusion dependent patients with low risk, del(5q) myelodysplastic syndromes (SintraREV): a randomised, double-blind, phase 3 trial |
Jul 2024 |
Lancet Haematology |
Myelodysplastic Syndromes (MDS) |
Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial |
Jul 2023 |
Lancet |
Myelodysplastic Syndromes (MDS) |
Are we ready to ring in a new upfront therapy in lower-risk myelodysplastic syndromes? |
Jul 2023 |
Lancet |
Myelodysplastic Syndromes (MDS) |
Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial |
Jan 2024 |
Lancet |
Myelodysplastic Syndromes (MDS) |
Are we ready to ring in a new upfront therapy in lower-risk myelodysplastic syndromes? |
Jun 2023 |
Lancet |
Myelodysplastic Syndromes (MDS) |
Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial |
Jun 2023 |
Lancet |
Myelodysplastic Syndromes (MDS) |
Progress in the Management of Pregnancy with Paroxysmal Nocturnal Hemoglobinuria: A Review |
Jan 2024 |
Journal of Women's Health |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
Romiplostim for Treatment of Children and Young Adults With Severe Aplastic Anemia and Myelodysplastic Syndrome |
May 2024 |
Journal of Pediatric Hematology/Oncology |
Aplastic Anemia |
Content validity of patient-reported outcomes for use in lower-risk myelodysplastic syndromes |
Aug 2020 |
Journal of Patient-Reported Outcomes |
Myelodysplastic Syndromes (MDS) |